# Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

> **NCT05004974** · PHASE2 · UNKNOWN · sponsor: **The Fourth Affiliated Hospital of Zhejiang University School of Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT05004974
- **Lead sponsor:** The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-26
- **Primary completion:** 2023-09-01
- **Final completion:** 2025-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05004974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05004974, "Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05004974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*